We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AVNR
126
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
-38,513,713
Closed -$653M
AST
127
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
-16,775
Closed -$54K

Similar funds

Julian Baker's Q1 2015 Portfolio in Review

As of Q1 2015, Julian Baker held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Julian Baker withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier.

Against the trend, Julian Baker opened a new position in Invitae Corporation worth $110M.

  • Julian Baker's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Julian Baker added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Julian Baker's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Julian Baker fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Julian Baker's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Julian Baker opened 18 new positions and closed 10 in Q1 2015.
  • Julian Baker's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.